KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Long-Term Deferred Tax (2016 - 2019)

Bio-Rad Laboratories (BIO) has disclosed Long-Term Deferred Tax for 11 consecutive years, with $138.0 million as the latest value for Q4 2019.

  • On a quarterly basis, Long-Term Deferred Tax rose 80.87% to $138.0 million in Q4 2019 year-over-year; TTM through Dec 2019 was $138.0 million, a 80.87% increase, with the full-year FY2019 number at $138.0 million, up 80.87% from a year prior.
  • Long-Term Deferred Tax was $138.0 million for Q4 2019 at Bio-Rad Laboratories, up from $76.3 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $138.0 million in Q4 2019 to a low of $76.3 million in Q4 2018.
  • A 5-year average of $102.2 million and a median of $99.5 million in 2015 define the central range for Long-Term Deferred Tax.
  • Peak YoY movement for Long-Term Deferred Tax: plummeted 32.77% in 2017, then surged 80.87% in 2019.
  • Bio-Rad Laboratories' Long-Term Deferred Tax stood at $99.5 million in 2015, then increased by 18.39% to $117.8 million in 2016, then tumbled by 32.77% to $79.2 million in 2017, then fell by 3.66% to $76.3 million in 2018, then skyrocketed by 80.87% to $138.0 million in 2019.
  • Per Business Quant, the three most recent readings for BIO's Long-Term Deferred Tax are $138.0 million (Q4 2019), $76.3 million (Q4 2018), and $79.2 million (Q4 2017).